SESSION TITLE: Education, Research, and Quality Improvement
SESSION TYPE: Original Investigation Poster Discussion
PRESENTED ON: Monday, October 24, 2016 at 12:00 PM - 01:30 PM
PURPOSE: The Advisory Committee on Immunization Practices (ACIP) recommended routine use of pneumococcal conjugate vaccine (PCV13) for adults age 19 through 64 years with immunocompromised conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants and all adults aged 65 years or older. PCV13 should be administered to all eligible adults in addition to the pneumococcal polysaccharide vaccine (PPSV23)1. We think that the PCV13 is still underutilized by general practitioners as well as other medical sub-specialty physicians including pulmonologists. We conducted this study as quality improvement project to estimate the number of inpatients who could potentially benefit from the PCV13 vaccine.